Advanced search
Start date
Betweenand

Synthesis and discovery of molecular mechanisms of some novel conjugated unsaturated ketones designed as anticancer agents

Abstract

A number of candidate anticancer agents have been designed and discovered in the laboratory of Professor Dimmock. These compounds display potent inhibitory effects on cell proliferation or are lethal to tumours. It is important to find the modes of action of representative lead molecules. The research group of Professor Marins has considerable experience in finding the ways in which cytotoxin exert their effects. When this information is to hand, then analogs may be discovered keeping in mind the shape and electronic properties of the molecular targets. The goal is that these compounds can be constructed with greater interaction of the drug molecule with the target enzyme or gene. The focus of this proposal is therefore to find compounds which have some (ideally all) of the following characteristics which (I) display greater toxicity to tumours than non-malignant cells (II) have low in vivo toxicity (III) possess desirable physicochemical properties and (IV) tumours are not resistant to them. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
JÉSSICA R. NOGUEIRA; FLÁVIA A. VERZA; FELIPE NISHIMURA; UMASHANKAR DAS; ÍCARO P. CARUSO; ANA L. FACHIN; JONATHAN R. DIMMOCK; MOZART MARINS. Molecular Docking Studies of Curcumin Analogues against SARS-CoV-2 Spike Protein. Journal of the Brazilian Chemical Society, v. 32, n. 10, p. 1943-1955, . (19/03074-1, 18/50008-1)
VERZA, FLAVIA ALVES; DAS, UMASHANKAR; FACHIN, ANA LUCIA; DIMMOCK, JONATHAN R.; MARINS, MOZART. Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy. CANCERS, v. 12, n. 6, . (18/50008-1, 19/03074-1)